HLX07(Anti-EGFR mAb) in Patients With Advanced or Metastatic Solid Tumors

Inclusion Criteria: * Volunteer to participate in this clinical study; completely understand and know this study as well as sign the informed consent form (ICF); * Aged ≥ 18 years, ≤ 75 years; * Patients must have histologically confirmed malignant solid tumors which are advanced or metastatic, have failed prior standard treatment, and be intolerant or ineligible for standard therapy; * Measurable disease according to RECIST Version 1.1; * Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1; * Expected survival 12 weeks; * Adequate organ function; * For fertile female subjects, the pregnancy test must be negative within 7 days before the first dose; Exclusion Criteria: * Prior anti-EGFR (including EGFR ADC) monoclonal antibody therapy; * A history of other malignancies within two years, except for cured Localized tumor; * Participants with any prior allogeneic solid organ or bone marrow transplantations; * Symptomatic brain or meningeal metastases (unless the patient has been on \> treatment for 3 months, has no evidence of progress on imaging within 4 weeks prior to initial administration, and tumor-related clinical symptoms are stable); * Uncontrollable pleural effusion, pericardial effusion or ascites requiring repeated drainage; * Active clinical severe infection;